Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease

• Päätekijät: V. I. Ignatyeva (Tekijä), S. V. Moiseev (Tekijä), N. M. Bulanov (Tekijä), E. A. Karovajkina (Tekijä), A S. Moiseev (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: IRBIS LLC, 2019-01-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency of the enzyme α-galactosidase A and characterized by the risk of renal failure combined with cardiovascular and CNS complications. According to the currently available information, the early start of enzyme repla...